Seres Therapeutics
MCRB
123 hedge funds and large institutions have $588M invested in Seres Therapeutics in 2022 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 41 increasing their positions, 35 reducing their positions, and 16 closing their positions.
50% more call options, than puts
Call options by funds: $1.87M | Put options by funds: $1.24M
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
17% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 35
3% more funds holding
Funds holding: 119 → 123 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.45% less ownership
Funds ownership: 4.67% → 4.22% (-0.45%)
21% less capital invested
Capital invested by funds: $743M → $588M (-$155M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$5.58M |
| 2 |
Jennison Associates
New York
|
+$4.48M |
| 3 |
EP
Eversept Partners
New York
|
+$1.78M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.44M |
| 5 |
Millennium Management
New York
|
+$1.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$74.3M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$3.59M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.47M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.77M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.63M |
MCRB Hedge Fund Activity: Q4 2022 in Review
123 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q4 2022, worth a combined $588M — down 21% from $743M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new MCRB positions and 16 closed out — a net gain of 4 holders — while 41 added to existing stakes and 35 trimmed.
The largest buyer was State Street, adding an estimated $5.58M. The largest seller was Janus Henderson Group, cutting an estimated $74.3M.
- 123 institutional investors held Seres Therapeutics (MCRB) as of Q4 2022, up from 119 in Q3 2022.
- Funds reported $588M of Seres Therapeutics stock for Q4 2022, down 21% quarter-over-quarter.
- 20 funds opened new Seres Therapeutics positions in Q4 2022 and 16 closed out, a net change of +4 holders.
- The largest Seres Therapeutics buyer in Q4 2022 was State Street, an estimated $5.58M added.
- The largest Seres Therapeutics seller in Q4 2022 was Janus Henderson Group, an estimated $74.3M sold.
Based on aggregated 13F filings for Q4 2022.